Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies
Date du début: 1 janv. 2009,
Date de fin: 30 juin 2013
Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cells in the initiation, progression and metastasis of malignancy. The objective of the collaborative integrated project INFLA-CARE is to structure a European collective of scientific and technological excellence in the field of ‘Inflammation & Cancer’ which will capitalise on the available expertise and develop effective anti-inflammatory strategies and novel agents for cancer prevention and treatment. The project will specifically seek to identify molecular and cellular targets for cancer therapy through the development and systematic study of state-of-the-art pre-clinical models of inflammation-driven cancer. By mobilising the outstanding research experience and technological capacities of the network participants, the program will accelerate the translation of knowledge obtained by basic research into new diagnostic and therapeutic strategies which will be used for the detection, prevention and improved management of several types of human cancer. INFLA-CARE will also ensure spreading of scientific excellence and dissemination of knowledge beyond the network, by encouraging innovation and transfer of knowledge and by raising public understanding of scientific and health issues. The impact of the program is therefore expected to be multi-dimensional, namely scientific, educational and innovation-related, enhancing European competitiveness and addressing major scientific issues and societal needs.
Avenue du General Sarrail 8
94010 CRETEIL CEDEX
Bonjour, vous êtes sur la plateforme Région Sud Provence-Alpes-Côte d’Azur dédiée aux programmes thématiques et de coopération territoriale. Une équipe d’experts vous accompagne dans vos recherches de financements.
Contactez la Région Sud Provence-Alpes-Côte d'Azur
Vous pouvez nous écrire en Anglais, Français et Italien